Several reasons may explain this expansion. The search for carcinogens, characterrzed by complex exposure circumstances and possibly weak effects, has become increasingly difficult with traditional epidemiological approaches. An example is the investigation of the role of diet, in particular early in life, in breast carcinogenesis (Okasha et al, 2A$) .In parallel, increasing knowledge of mechanisms of carcinogenesis led to the proposal of models involving genetic and epigenetic events, as well as cellular and histological alterations. These models, which need to be tested in human studies, represent a theoretical framework for molecular epidemiological research. Furthermore, developments in molecular biology and genetics, such as the use of robots and the increasing throughput of automatic analytical equipments, allow the large-scale application of assays that would otherwise be very resource intensive.
It is useful to consider biomarkers in general and molecular epidemiology tools in particular within the larger framework of epidemiological studies. Epidemiology aims 1.09 110 BACKGROUND .a r-.--.'. . '. I at identiiying cleterminants of diseirse rtnd qurrntifying thcir role, while tirking intt-r zlccount soLlrces r>f randorn zrnd systenrrrtic error (bias and confounding), as well as firctors thirt rnodify the effect of tl-re deternrinant(s) oi interest . To e large extcnt, biornarker-barsed epidemiologicatI stuclies fit into tlre sirme frzrmework: They represent epidemiological studies, in which risk factors, oLttcomes, confounders,, or effect modificrs irrc nreasured with biomarkers. Similerrly, the s:.lme argLrmcnts should be zrpplied to the design, analysis, ernd interpretation of biomarker-based and more tracJitionrr I epidem iologic:r I studies.
h-r practice, there is a continuum from the development of biomarkers to be applied in human str-rdies, to their characterization in early field studies, to their application in fLrll-scale epiderniologicirl investigarions (Garcirr-Clos:ls et :.r1, 2006) . However, these logical steps rrre often bypasscd, with promising but yet unvalidzrted biomarkers being appliecl in humarn str-rclics. While this pattern ref-lects the vivacity of rr young discipline, it rTl()re cautious irpproach is needed in order to avoid misuse of researrclr resources.
In the context of epidemiological studies, a birlrnirrker has been defined as ir substance. strLrcturc, or process thirt (1 ) can be measured in the humrrn body or its prodLtcts and (2) may influence the incidence or outcome of cliserrse in humirn populations (Workshop Report,, 1997) .It is important to bear in mind the distinction between marker, assay, and measllrement. While the marker is the variable to be measured, the assay is the test used to measLl meesufelllent is :.rtr ir marker.
A distinction has be markers of exposure. disease, and susceptit hle 5-l) . This distinct what arbitritry. For e:
irberrations hrrve beet rnoniror exposLrre to ogens (Tucker et .Fs rlrc test used to measure the marker, and the nreilsurement is an individual value of the rrrrr rker.
A distinction has been made between biorrrrrrkers of exposure, intermediate events, ,.lisease, and susceptibility . This distinction, however, is somervhat arbitrary. For example, chromosomal .rbcrrations have been used for decades to rrronitor exposure to environmental carcin-()qens (Tucker et al, 7997) . From this point ,rf view, they can be classified as biomarkers ,,f exposure. However,, growing evidence pointS toward a role of chromosomal aberr.rrtions for prediction of cancer risk,, irre\pective of exposure (Norpper et arl, 2006) .In t his respect, they can l're seen as intermediate biomarkers. Furthermore, it is important l() notice that irny scheme, such as that re-1'tresented irt Fieurc 5--1, reflects our cLrrrent rrnderstanding of the complex biological 1',henomerron oi cirrcinogenesis arnd our alri|-ity to rrci.rsLrrc cvcnts th:rt arre considered relevant to it. In othcr words, the stcps in thc cirrcinogenic process depicted irr Figure 5 -3 represent "boxes" wlrbre we irllocate available bionrirrkcrs: In fact, rrore ernpl-rasis is given in thc sclicnrc to thc carly steps (internal dosc, biologically cffcctive d<lse, etc) rhan to rhc latcr stcps sirnply bccrrusc <lf the larger availability of markers-and their more straightforward interpretation-to measure the former as compared to the latter events. The increase in the understanding of the late steps in carcinogenesis, and the development of relevant and valid biomarkers, represents a main challenge to molecular cancer epidemiology.
EXPOSURE BIOMARKERS
In many instances, epidemiologic research is hampered by misclassification of exposure ascertained, for example, by means of questionnaires, interviews, or job histories. The rationale for using biomarkers is to measure the biologically relevant exposure more precisely. In some instances, there is an obvious improvement in using an exposure biomirrker. Aflatoxin provides a good exarnple in which exposure biornarkers represent a step forw:.rrd in the identific:rtiorr of the human cancer hazerrd. The fungus Aspergillus flauus is a contaminant of foodstuffs, in particular cereals and nuts. Exposure is common in 'West Africa and Eirst Asia. Depending on storage conditions, A.
flauus n-ray prodLrce a toxin,, called aflatclxin,' with strong hepatotoxic and carcinogenic properties in animal models. It is difficult to tinghirni gical investigatior-rs )6 ). Hor,vever, tl-rcse ,1'rirssccl, with pronrc1 biomarkers being cs. Whilc this pety oi a y()un [l cliscirrpproaclr (Rossi et al, 2005) HPV infection rrnd orirl c,rncer risk lMork et al, 2001) Horrrones and brerrst cilncer risk (Kiraks et al, 200 l) Aflatoxin adducts and liver cancer risk (Ross et al., 1992) Ethylene oxide irclducts (Schulte et al, 1992) Chromosomirl rrberrirtions ancl cirncer risk (Boffetta et al. 2007 ) PAH-DNA acldrrcts ancl lung cllncer risk (Tang et al, 2001) TP-S3 mr.rtirtions in lung cirncer (l- know whether the food humans have consumed h:.rs been contaminated by zrf'l:.rtoxin. Studies on the carcinogenic effect o[ aflatoxin are therefore limited by the difficulty of determining exposure statLrs at the individual level, although ecological analyses have indicated a higher incidence of hepatocellular carcinomel in areas witl'r frequently contaminated food than in neighbouring areas with less frequent contamination.
The identification of serum and urine biomarkers of aflatoxin exposure-namely urinary metabolites of aflatoxin itself and of its adducts formed with DNA-paved the way for important developments. Table 5 -2 reports an increased risk of hepatocellular carcinoma in the first study using exposure biomarkers in subjects with samples collected and stored prospectively. Individuals with any urinary marker of erposure had a 2.4-fold increased risk of liver cancer relative to individuals without markers; the relative risk was as high as 4.9 among individuals positive for the urinary adduct degradation product AFB1-N7 guanine (Ross et al, 1992) . These results, replicated in other popr-rlations, provide strong evidence of ar causrll irssociirtion l-retween afliltoxin and liver cancer in humans (IARC, 2002) .
Exposure markers measure the prescnce or level of exogenous agents (eg, pollutants), agents formecl endogenou s I y (eg, h<l rnro nes), the metabolites of exogenolrs and endogenoLrs agents., the prclducts Of the interaction of the agents or the metabolites with macromolecules (eg, DNA adducts), ancl physiological responses elicited by the exposure (eg, antibodies).
The use of biomarkers to measure exposure is not a panacea; the performance of exposure biomarkers should be compared to that of other exposure-assessment methods, such as medical records, qLlestionnaires, and environmental monitoring. Main concerns are the relevance of the biomarker to the exposure of interest, its specificity (eg, chemicals often share common metabolites). and the characteristics of the assay, including sensitivity, kinetics, source of variability, and effect modifiers (Rothman et al, 1995 (Wei et al, 2000) vide strong evidence n between aflatoxin rans (IARC, 2002) . leasure the presence lents (eg, pollutants), ously (eg, hormones), 'genous and endogects of the interaction etabolites with macadducts), and physiited by the exposure :rs to measure expothe performance of rould be compared to assessment methods, ;, questionnaires, and ring. Main concerns re biomarker to the s specificity (eg, chemmon metabolites), of the assay, includsource of variabiliry, othman et al, 1995) . fe of blood and urine to chemicals varies Source: Ross et al,1992. from a few hours (eg, chlorinated hydrocarbons) to years (eg, dioxins) (Coggon and Friesen, 1997) .
Most biomarker-based studies, of both prospective and retrospective design, rely on a single biological sample. This represenrs a drawback as compared to traditional exposure assessment based on, for example, questionnaires or interviews. With the latter approaches, historical reconstruction of variations in exposure is-at least in some instances-feasible. An example is the assessment of tobacco smoking. Biomarkerbased approaches, such as the measurement of nicotine or its metabolites in plasma, provide a precise indication of recent exposuf€; However, no biomarkers are currently available to assess cumulative tobacco consumption, or other time-related aspects of exposure that are important predictors of tobacco-related cancer risk.
Exposures in cancer epidemiology are often time-related variables. Moreover, both carcinogenesis models and empirical evidence strongly point toward the importance of induction and latency periods in cancer occurrence, the importance to evaluate both duration and intensity of exposure, and the need to assess changes in disease risk after cessation of exposure. The goal of exposure assessment is the reconstruction of a full history of exposure during relevant time periods. Different methods for exposure assessment (eg, biomarker-based versus questionnaire-based) should be evaluated on how well they accomplish this objective and on how well they complement each other.
While most biomarkers measure recent exposure, there are ways to use them to assess temporal changes. One approach is to collect repeated samples from subjects enrolled in prospective studies. Iflhile theoretically excellent, this option is often financially and logistically prohibitive. A compromise is the collection of repeated biologic samples from a fraction of the original cohort. If the sample is representative and large enough, it becomes possible to identify predictors of temporal changes in the biomarker and apply them to the whole study population. A more serious problem exists in retrospective studies, in which measurement of exposure biomarkers at the biologically relevant time (eg, several years before onset of the disease) is generally not possible.
\il7hen biological samples are avallable on a subset of the study population, it is possible to model exposure in a way similar to that described previously for repeated samples. For example, in a study assessing cancer risk from dioxin exposure among 1,167 chemical workers from the Netherlands, recent serum dioxin measurements were available for 1.44 individuals, while a detailed occupational history was available for all workers (Hooiveld et al, 1998) . In an analysis of the results from 144 workers, three factors-namely years in main production, employment before '1,970, and exposure during an industrial accidentexplained 85% of the variance in serum dioxin level. The application of these factors to the occupational histories, and the incorporation of terms accounting for the kinetics of dioxin accumulation during exposure and release after cessation of exposure, generated an estimated maximum level of exposure for all workers. In other instances, a biomarker can be used on a subset of the study population to validate exposures estimated by other means.
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A special group of exposure markers are adducts formed by carcinogens with DNA and proteins (Farmer,2004) . DNA adducts are directly relevant to carcinogenesis, since they reflect the interaction of the active compound with the relevant cellular target. They also integrate internal dose and repair capacity, thus providing a relevant indicator of biologically active dose (Rundle, 2006) . However, the drawbacks in their use in epidemiology are the low levels detected in most exposure circumstances and the relatively short half-life. Some techniques to measure adducts are more sensitive, although this is often obtained by losing specificity. The half-life of white blood cells, which are often used to measure DNA adducts, is variable, but in general rather short. On the other hand, the detection of adducts to proteins-mainly albumin and hemoglobin-allows a measure of internal dose integrated over several weeks or months. In general, DNA and protein adducts represents a useful complement to other approaches of exposure assessment, but in very few circumstances have they provided critical novel information, in either qualitative or quantitative terms, to epidemiological research.
The use of exposure biomarkers poses additional methodological problems. As discussed in the following, epidemiological results based on exposure biomarkers are potentially subject to bias and confounding, as are other types of observational studies. An additional problem exists when exposure markers are used in retrospective casecontrol studies: their possible dependence on the disease process. For example, lipid metabolism might be altered in breast cancer and other hormone-dependent neoplasms (Demark-'Wahnefried et al, 2001 .), resulting in possible bias in the measurement of compounds stored in adipose tissue, such as many organic contaminants. Despite the potential limitations, exposure biomarkers represent an important tool in cancer epidemiology. Technological developments are rapid in the field, improving the accuracy, sensitivity, and precision of the assays and facilitating the application of the markers to large-scale population studies.
INTERMEDIATE BIOMARKERS
Intermediate biomarkers measure earlyin general nonpersistent-biological events that take place in the continuum between exposure and cancer development. These events include measure of cellular or tissue toxicity; chromosomal alterations; changes in DNA, RNA, and protein expression; and alterations in functions relevant to carcinogenesis (eg, DNA repair, immunological response). Similar to exposure markers, these markers are generally measured in easily accessible biological samples, typically blood components. Several of these assays offer a potentially important contribution to molecular epidemiology, because of their direct relevance to carcinogenesis and the parallel development of intermediate-or largethroughput technical platforms (eg, microarrays).
The use of DNA and RNA expression arrays in large-scale population studies has started, and their contribution is expected in the next few years (Gunn and Smith,2004) . As proteins and peptides are more stable and relatively easier to measure than RNA and DNA, proteomics and metabolomics represent interesting new approaches to the investigation of intermediate events in molecular cancer epidemiology.Also in this instance, however, the application to largescale population-based studies is only startirg, and the characteristics and performances of the biomafkers are not fully understood. An additional challenge brought by microarray and proteomic analysis is the complexity of data, since several hundreds or even thousands of data points are generated for each sample, which poses novel statistical challenges, including an increased likelihood to produce false-positive results (see following).
Chromosomal alterations measured in peripheral lymphocytes have been used for monitoring exposure to mutagens and carcinogens. In recent years, several cohort I studies have been established by measuring the occurrence of cancer among individuals who underwent chromosomal aberration testing (Norppa et al, 2006) . Four such cohort studies have been reported: A meta-analysis of their results suggests that higher levels of chromosomal aberrations are associated with a modest increase in can€er risk (Table 5 -3)-the cancers with the highest excess risk were those of the digestive system.
Despite the fact that they are considered primarily biomarkers of exposure (see previous), DNA adducts have been used to predict cancer risk in several prospective studies (Phillips, 2005) . Although the exact role of DNA adducts in predicting cancer risk has still to be elucidated, this is an additional example of the artificial distinction between "exposure" and "effect" biomarkers, and the need to study the exposuredisease relationship as a continuum.
DISEASE BIOMARKERS
As in the case of exposure markers, the use of biomarkers to measure the outcome of an epidemiological study (rypically cancer) has the aim to increase the validity of the measurement-that is, to increase the specificity and the sensitivity in the definition of the outcome. For example, microarraybased techniques to measure the expression of a large number of genes has led to the discovery that cases of breast cancer indistinguishable according to traditional histological classifications may show profoundly different patterns of genetic expression (Sorlie, 2004) .
Alterations (eg, mutations, deletions, epigenetic modifications) in genes with a role in carcinogenesis or a characteristic cytogenetic alteration, rather than the tumor itself, might become the outcome of a molecular epidemiological study. Studies based on biomarkers of disease are best suited in a prospective design, since the identification of early events relevant to carcinogenesis would hopefully impinge on preventive strategies. For example, mutations typical of tobaccorelated cancers have been found in sputum samples of heavy smokers, suggesting that they can be used as markers of lung cancer (Kersting et al, 2000) .
Disease biomarkers can also be used in retrospective designs, in which only diseased individuals are enrolled. In such caseonly studies, comparisons are made among subgroups of cases with differences in the profile of genetic mutations (or other molecular characteristics). For example, different frequencies and patterns of mutations in TP53 have been detected in lung cancer, in correlation with tobacco smoking and exposure to other carcinogens (Pfeifer et al, 2002 ).
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BACKGROUND As in the case of exposure markers, the time coordinates of early effect markers are crucial for their application in molecular epidemiology. While adequate knowledge of the natural history is lacking for most human neoplasms, models of carcinogenesis developed for various tumors, eg, colon cancer (Fearon and Vogelstein,1990l, stomach cancer (Correa, 1.992) , and head and neck cancer (Sidransky, L997) , provide a framework for the application of effect markers.
SUSCETTTIBILITY MARKERS
The broad interindividual variabiliry at both the genetic and the epigenetic levels provides a framework to explain the inherited susceptibility to cancer. Susceptibility markers can be measured at the genotypic level and at the functional (phenotypic) level. The advantages of genotypic markers are their stability across tissues and time, and the growing throughput of genotyping technologies. Phenotypic markers, on the other hand, integrate the effect of multiple genes, epigenetic phenomena, and posttranslational modifications with respect to given characteristics such as DNA repair: Their implementation in large-scale population studies, however, remains limited.
The most commonly studied genetic variants are single nucleotide polymorphisms (SNP); other types of variants include microsatellites, deletions, insertions, gene amplifications, and variations in the number of gene copies (Redon et al, 2006) . Early studies of susceptibility markers considered only one or few variants in candidate genes; technological developments have later conferred the ability to look at hundreds or even thousands of variants in a panel of genes. In the last years, the analysis of a large number of variants has become possible (current microarrays include several hundreds of thousands of SNP. but this number is expected to grow in the near future). In such genome-wide association studies any effort to select variants and genes based on a priori functional knowledge has been abandoned.
IThile a detailed discussion of genetic cancer epidemiology is beyond the scope of this chapter, it should be stressed that few variants conferring modest, at most, increases in cancer risk have been consistently found. It is likely that most of the genetic susceptibility to cancer arises from a combination of deleterious variants in different genes, each providing only a marginal excess risk. Furthermore, it is plausible that most of the effect occurs from the combination of genetic make-up and exposure to endogenous or exogenous factors (so-called "geneenvironment interactions"l see following) (Hunter, 2005) . The high-throughput genotyping approaches developed in recent years have started to be applied to genetic cancer epidemiology. It is expected that they will contribute substantially to the understanding of mechanisms underlying genetic susceptibility, and eventually mechanisms of human carcinogenesis.
Epigenetic alterations, particularly changes in promoter methylation status, are increasingly used as markers of carcinogenesis. Methylation status in lymphocytes and other surrogate tissues may reflect inherited characteristics that are relevant to individual susceptibility, possibly in relation with lifestyle and environmental exposures.
Functional (phenotypic) markers can be used to complement the information provided by the analysis of genetic variations. In particular, the individual abiliry to repair DNA damage has been investigated using different types of assays-such as host-cell reactivation assay, mutagen sensitiviry, Comet assay-in case-control settings (Spitz et al, 2003) . In general, cancer cases have shown a decreased DNA repair capacity as compared to controls, but the interpretation of these results is hampered by the small sample size and the use of lymphocytes as surrogate cells. The technical complexiry of these assays has so far prevented their application in large-scale prospective studies.
BIAS
Three main types of bias are recognized in epidemiology, and all three may operate in biomarker-based studies (Rothman and Greenland,1996) . Selection bias arises from lack of comparability o the study. For example, be more (or less) likell study than exposed cc bias involves different f'erential misclassificat' with respect to disease c biomarker-based studir encompasses the issues reproducibility, and st F'inally, confounding i trias, generated by co' factors other than tho following).
Selection bias can be identifying the study optimizing the r€SponS, it can be controlled in t tifying factors that are and by controlling thr Unfortunately, many r logical studies pay to( the definition of sourc( lcction of participants. common in studies of p it is considered that an' ipants is unlikely to be gcnetic factors under st $pective studies are les bias than retrospective lack of comparability of groups included in rhe study. For example, exposed cases might be more (or less) likely to participate in a study than exposed controls. Information bias involves differential or even nondifferential misclassification of participants with respect to disease or exposure status. In biomarker-based studies, information bias encompasses the issues of inherent validity, reproducibility, and stability of markers. Finally, confounding is a special form of bias, generated by co-exposure to causal factors other than those under study (see following).
Selection bias can be avoided by properly identifying the study population, and by optimizing the response rate. Furthermore, it can be controlled in the analysis by identifying factors that are related to selection and by controlling them as confounders. Unfortunately, many molecular epidemiological studies pay too little attention to the definition of source population and selection of participants. This is particularly common in studies of genetic factors, since it is considered that any selection of participants is unlikely to be associated with the genetic factors under study. In general, prospective studies are less prone to selection bias than retrospective studies.
BIOMARKER VARIATION
Sources of variation in biomarker-based measurements might arise from intergroup (eg, cases versus controls) variability: This is the very phenomenon molecular epidemiological studies usually aim to address. However, other sources of variation exist that generate misclassification. Interindividual variability might be due to genetic or environmental factors affecting the biomarker under study. Intraindividual variability refers to components of variation such as diurnal variation in hormonal level. Finally, measurement error might arise from sampling and laboratory variation. Table 5 -4 provides some examples of sources of variation for selected biomarkers used in molecular cancer epidemiology (Vineis, 1997) .
Proper precautions should be taken to minimize the sources of variation other than intergroup variability. Such sources are numerous: the circumstances under which biological samples are taken, processed, stored, and analysed; the technical aspects of the assays; etc. It is important to ensure that, if all sources of variation cannot be controlled (as it is often the case), they should apply equally to the groups being compared. Therefore, if long-term storage of samples might affect the measurement, it is important to match cases and controls in the study by duration of sample storage. In this situation, misclassification is said to be "nondifferential" (ie, acting equally on the groups being compared). Nondifferential misclassification generally produces bias toward the null value-that is, it obscures an existing association, but it does not generate one when none exists, nor does it accentuate an existing positive or inverse one. On the other hand, a misclassification that is "differential" with respect to case/control (or exposed/unexposed) status generates a bias in an unpredictable direction. For example, if there is substantial interbatch (or interreader) variability in the measurement, the inclusion of samples of cases and controls in different batches would generate differential misclassification, while a proper mix of samples in each batch would at worst result in nondifferential misclassification.
TRANSITIONAL STUDIES
The issue of variation in biomarker-based measurements impinges on the need to validate biomarkers before application to largescale studies. This is the domain of so-called transitional studies, which aim to characterize the biomarker itself rather than the underlying biological phenomenon. The aspects assessed by transitional studies include intra-and intersubject variability, feasibiliry of application of a biomarker in field conditions (and optimization of its use), identification of determinants with confounding and effect-modifying potential, and exploration of biological mechanisms underlying the variation of the marker. Transitional studies may involve healthy individuals, patients, or subjects with specific exposures (eg, groups of workers). Three rypes of transitional studies have been described in the continuum between development of a new assay and its large-scale application to human populations (Table  5 -5) (Schulte and Perera, 19971' Rothman et al, 1995) .
Developmental transitional studies have several goals. They aim to identify the biological phenomena measured by the marker and their relevance to the exposure, the disease, or the host variables of interest. In addition, developmental studies address the reliability (reproducibility) of the newly developed marker, by blindly measuring replicate samples. These samples should be representative of the values likely to be found in populations that the marker has to be applied to (Rothman et al, t995) . Assessment of reliability encompasses both random laboratory variation and nonrandom (systematic) error. Principles for assessment of marker reliability have been proposed (Vineis et al, 1993; Droz, 1993) . Developmental transitional studies should also address aspects of relevance to field applications such as kinetics and stability of the marker. They should contribute to the clarification of the temporal relevance of the biomarker in relation to the underlying biological phenomenon (Droz, 1993) .
The main aim of characterization-type transitional studies is to assess interindividual variation in the marker and to reveal genetic and acquired factors that contribute to such variation. When applied in the field, interindividual variation of the marker will be studied in conj sure or the outco of interindividual r known and, to a c, for. One particular variability is the d level of the marker tissues, since field sr on samples of surr blood. The identificr the level of a marke acterization of the r the interpretation o lar epidemiological the finding that a m is a modifying facto sure provides impor metabolic pathways sure of interest.
Applied transition the relationship ben phenomenon that it ir ie, the relationship marker or between n example, the associa to butadiene and sevr mutations in the HRI ied, in order to assess markers in predictin exposed workers (Alt (Table  ra, L997; Rothman itional studies have L to identify the biosured by the marker , the exposure, the iables of interest. In .al studies address :ibility) of the newly blindly measuring e samples should be values likely to be hat the marker has hman et al, 1995). y encompasses both :iation and nonran-:. Principles for as-:liability have been 7993; Droz, 1, 993) . onal studies should f relevance to field etics and stability of ld contribute to the nporal relevance of )n to the underlying . (Droz, 1993) . h,ar acteriza ti on -type to assess interindinarker and to reveal Itors that contribute r applied in the field, n of the marker will 997\ :tron, processlng, storage sion : in representative human 'nal ) exposure-biomarker cs, and of potential ers of various populations biomarker be studied in conjunction with the exposure or the outcome of interest. Sources of interindividual variation should then be known and, to a certain extent, controlled for. One particular aspect of interindividual variability is the difference in presence or level of the marker in different organs and tissues, since field studies often have to rely on samples of surrogate tissues, typically blood. The identification of factors affecting the level of a marker goes beyond the characterization of the marker and impinges on the interpretation of the results of molecuIar epidemiological studies. For example, the finding that a metabolic polymorphism is a modifying factor for a marker of exposure provides important information on the metabolic pathways relevant to the exposure of interest.
Applied transitional studies aim to assess the relationship berween a marker and the phenomenon that it is considered to indicate, ie, the relationship berween exposure and marker or between marker and disease. For example, the association berween exposure to butadiene and several markers, including mutations in the HRPT gene, has been studied, in order to assess the usefulness of these markers in predicting cancer risk among exposed workers (Albertini et al, 2001 ).
CONFOUNDING
The use of biomarkers does not prevent confounding. For example, an association between tobacco smoking and cancer of the uterine cervix has been observed in many populations but it is likely to be confounded by infection with the human papilloma virus (HPV), a cause of cervical cancer. In many populations, smokers are more frequently positive for HPV than nonsmokers. Hence, HPV would be a confounder no matter how smoking, infection, and cervical cancer are assessed (via questionnaires, medical records, biochemical methods, or molecular techniques). Furthermore, to use biomarkers might introduce confounding. If, for example, workers occupationally exposed to polycyclic aromatic hydrocarbons (PAH) have a higher consumption of tobacco (an important source of PAH) than other workers, then the assessment of occupational exposure with a biomarker of PAH is confounded by tobacco smoking ( Figure 5-4) (Pearce et al, 1, 995) . This would have not been the case if occupational exposure were assessed without biomarker methods.
INTERACTION
Biomarkers have been widely applied to studies of gene-environment interactions and gene-gene interactions in the pathogenesis of cancer and other chronic diseases (Hunter, 2005) . Table 5 (Brennan et al., 2005) Dietary cruciferous vegetable intake -RR (95% CI)
High (reference) Medium GSTM1+ and GSTTI+ GSTMI+ and GSfi1-or GSTMI-and GSTTI+ GSTM1-and GSTT1- contain the potentially chemopreventive isothiocyanates. Polymorphism for genes encoding for the enzymes glutathione-Stransferase (GST) M1 and T1, are implicated in the metabolism of isothiocyanates (Brennan et al, 2005) . The apparent protective effect of high intake of isothiocyanate-rich diet was stronger among carriers of the null genotypes in the GST enzymes than in carriers of the wild-rype genotype in one or both genes.
Molecular epidemiology studies addressing other types of interaction between two or more factors may be discussed following a similar approach. For example, in the study of aflatoxin exposure and liver cancer mentioned previously, the investigators addressed the possible interaction of aflatoxin with hepatitis B virus (HBV) (Ross et al, 1992) . \$7hen compared to HBVnegative subjects exposed to aflatoxin, the relative risk in HBV-positive subjects also positive for aflatoxin markers was 50, which was greater than the product of the relative risks for the two factors separately (4.8 for HBV and 1 .9 for aflatoxin). Thus a supermultiplicative synergism between aflatoxin and HBV in liver carcinogenesis is suggested. The wide confidence interval in the group with both exposures (6.4-560) precludes, however, rejections of the null hypothesis of no interaction according to a multiplicative model (4.8 xL.9 : 9.1). This wide interval also stresses another methodological concern in molecular epidemiological studies, namely the need for a large sample size.
RANDOM ERROR
From several of the examples quoted previously it is clear that an important problem in biomarker-based epidemiological research is the insufficient number of subjects included in each study. The main reasons for a small study size are logistical and financial constraints. Indeed, efry biomarkerbased measure introduced in epidemiology should be compared with traditional measures, and the possible gain in sensitivity and specificity of the biomarker measure should be considered in the light of the possible decrease in the number of study subjects.
Authors have proposed formulas to calculate the sample size needed to detect main effects and interactions among risk factors (Garcia-Closas and Lubin, 1999) .Molecular epidemiology studies often do not include a sufficient number of individuals, and this has been the reason for unstable and conflicting results. For example, many studies have been published on the possible association between slow acerylation polymorphism and bladder cancer risk. The biological rationale is that individuals with variants leading to reduced acerylation might have a reduced capacity to detoxify environmental bladder carcinogens, including aromatic amines. It is unlikely, however, that the relativerisk would be higher than, say, 1.5, and, in fact, recent meta-analyses confumed the presence of increased risk of the order of 40"/" (GarciaClosas et al, 2005) . Given that the frequency of the relevant polymorphic variant in Euro- pean populations is about 50y",,450 cases Since lack of statistical power is an imand the same number of controls are needed portant problem in molecular and genetic to achieve an 80"h power to detect a statisepidemiological studies aimed to detect tically significant relative risk of 1.4. If the weak associations, the independent conduct goal is to detect an interaction berween the of small-scale studies that address several polymorphism and an environmental factor hypotheses is a reason for the generation of (eg, tobacco smoking or occupational expomany false-positive results (Ioannidis et al, sure to aromatic amines), then the number of 2006a). This problem has been mainly adrequired cases and controls would be much dressed in the context of genetic association larger (between 2-and 20-fold, depending studies, and in particular as a consequence on the expected strength of interaction).
of the growing ability to measure a large As shown in Figure 5 -5, only 2 out of the number of genetic variantsl but it may af2gstudies ofNAT2polymorphismandblad-fect other areas of molecular epidemioder cancer included in a recent meta-analysis logical research. Guidelines for the reporthad an adequate size to detect the main efi.g of results and the interpretation of fect of the polymorphism, and only one "positive" associations have been proposed had the power to document a strong inter- (Ioannidis, 2005) . action with an environmental exposure. In recent years, large-scale studies have been pUBLICATION BIAS set up, in order to provide more robust results (eg, Slattery et al, 1998; A problem related to the generation of falseet al, 2005; . Another appositive results is the tendency to selecproach is the pooling of independently contively report significant results, in particular ducted studies (Ioannidis et al, 2005 direction. The net result is a biased underreporting of null results. As an example, several studies have been conducted on polymorphism of the CYP2D6 gene, which encodes for an enzyme possibly involved in the activation of lung carcinogens, and lung cancer risk. Figure 5 -5 shows the results of the 18 studies available for a meta-analysis (d'Errico et al, 1999) reported in terms of the logarithm of the relative risk for highrisk CYP2D5 polymorphism, and its standard error. Each study is identified by one dot, studies to the right of the figure are smaller than those to the left, and studies at the top are more positive than those at the bottom of the figure. If no publication bias existed, the pattern of such results should resemble a triangle (or a funnel), with larger studies converging on the left side around the central ("true") value, and smaller studies symmetrically dispersed on the right side. However, the empty side at the bottom right corner of the graph suggests that smaller studies were more likely to be reported if they showed a positive effect, and a formal analysis revealed publication bias for CYP2D5 and lung cancer (Table 5-7), that was due to studies published before rather than after 1993.
It may be argued that such an initial report of false-positive results should be considered no major scientific problem, since subsequent studies, aimed to replicate the early positive results, will eventually establish the truth. However, this approach is inefficient and represents an important waste of resources, more so when it comes to expensive molecular epidemiological studies. A preferable approach is to critically evaluate and report results on the basis of criteria other than-or including but not limited to-statistical significance (Ioannidi s, 2006) . Biological plausibility, possible sources of bias.and confounding, and numbers of tested associations are among such criteria. Statistical approaches have been proposed to take into account the possibility that significant results are generated by chance when many comparisons are made (Greenlan d, 1, 994) .In addition, authors should be encouraged to systematically report their results, even those that are "negative" or "null."
CONCLUSIONS
Since the term molecular epidemiology was proposed in 1,982 (Perera and \Teinstein, 1982) , molecular techniques have dominated biomarker research and have found an important and growing role in epidemiological studies. In several instances the application of a molecular approach has represented an important step beyond the evidence brought by traditional epidemiological methods. Assessment of exposure to aflatoxins, enhanced sensitivity and specificity of assessment of past viral in-fection, and detection of protein and DNA adducts in workers exposed to reactive chemicals such as ethylene oxide, are among the examples in which molecular epidemiology has contributed to the understanding of human cancer. In many other cases, however, initial promising results have not been confirmed by subsequent, usually methodologically sounder, investigations. They include in particular the search for low-penetrance genetic variants leading to modest increases of cancer susceptibility (Ioannidis et al, 2006b) .
If biomarkers are to offer new opportunities to overcome some of the limitations of epidemiology, then their added value over traditional approaches should be systematically assessed. Biomarkers should be validated and consideration of sources of bias and confounding should be no less stringent than in other rypes of epidemiological studies. Similarly, other aspects of the study such as determination of required sample size, statistical analysis, and reporting and interpretation of results should be approached with the same rigor as in epidemiology in general.
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